Backers of Jena, Germany-based Inflarx NV have turned their attention to the rest of the pipeline after the stock-jolting news from an independent data monitoring committee (DMC) responsible for the ...

Boston Scientific Corp. reported the latest setback in its transcatheter aortic valve replacement (TAVR) aspirations with the news that it is officially discontinuing worldwide sales of its Acurate ne ...

To overcome the current limitations of antitumor immunotherapy, in situ vaccine platforms based on intelligent microbes are gaining increased attention due to their ability to sustainably deliver ...

Epimab Biotherapeutics Inc. licensed out a development-ready KLK2/CD3 bispecific T-cell engager (TCE) for advanced prostate ...

Glycoengineering specialist Glycoera AG is preparing to take its extracellular protein degrader constructs into the clinic in the treatment of autoimmune diseases, after closing a $130 million series ...

The U.S. Trade Representative (USTR) is asking for help in its search for “freeloaders” that refuse to shoulder their share of the cost of biopharma R&D.

After reporting in April that its gastrointestinal reprogramming product (Garp) failed to meet the primary efficacy endpoint in a phase II trial in irritable bowel syndrome (IBS), Anatara Lifesciences ...

GSK plc knew a good thing when it swooped in nearly three years ago to rescue Spero Therapeutics Inc.’s oral antibiotic from a complete response letter (CRL). New pivotal phase III study data showed ...

The variety of blood cells decreases with age. Some are lost, while others become dominant, leading to a loss of functional ...

Four months after Vertex Pharmaceuticals Inc.’s U.S. FDA nod for Journavx (suzetrigine) as the first drug targeting NaV1.8 for treating pain, Eli Lilly and Co. is joining the potential competition via ...

University of Health Sciences and Pharmacy in St. Louis has described estrogen-related receptor α (ERR) modulators reported to be useful for the treatment of diabetes, amyotrophic lateral sclerosis, ...

Phosphoinositide signaling pathways have been implicated in the metabolic alterations associated with various human diseases, including breast cancer. The phosphatidylinositol-5-phosphate 4-kinase ...